Optimization of family planning service in Ukraine in the realization of modern strategy of woman health maintenance

Ю. Г. Антипкін, В. В. Камінський, Т. Ф. Татарчук

Abstract


The primary objective of the reproductive health services system and its individual institutions are, namely: to implement the strategy of women management starting from their fetal life to the old age and ensure quality of life in adolescence, reproductive and postmenopausal periods. Maternal and child death rates are above respectives rates in European countries, and utilization rate of modern contraceptive methods in Ukraine remains low. This can be explained by both, poor awareness of women and insufficient training of medical personnel. In this context, the top priority still is awareness-raising and further implementation of the strategy on reliable contraception means and methods along with effective preconception care as a potent component of family planning.

Taking into account modern global trends, the principal goal of Family Planning Service in Ukraine is to improve women’s quality of life and time of active ageing, which achievement can be facilitated by the implementation of 3 priority tasks:

• continued realization of the strategy on reliable contraception use and implementation of effective preconception care to abortions prevention and maternal and newborns mortality rates reduction;

• reduction cardiovascular and oncological diseases incidence rate in women through development and implementation of respective screening programs, informational and preventive measures;

• implementation of best international practices with respect to Family Planning Service efficacy, review and update of family planning clinical protocol with further implementation of such practices at the national and regional levels.

Considering this, the Resolution of Advisory Board outlines the main tasks for the implementation of modern international experience and its further implementation at the national level, and amendments to clinical protocol of primary, secondary (specialized) and tertiary (highly specialized) medical care (approved by the order of MOH of Ukraine No. 59 dated January 21, 2014) “Family Planning”. The main additions and comments touched upon the issues of micronutrient status and reproductive health of women, contraceptive methods for women in perimenopause, counseling and selection of contraceptive methods for HIV-positive women. Particular attention was paid to counseling and selection of contraceptive methods for women military personnel.


Keywords


family planning; resolution; contraception

References


Evsina, O.V. “The quality of life in medicine – an important indicator of patient health status.” Electronic scientific journal “Personality in a changing world: health, adaptation, development” 1 (2013):119–33.

Order of the MOH and National Academy of Medical Sciences of Ukraine No. 1030/102 from 29.11.2013. “About improvement of family planning system and reproductive health care in Ukraine.”

Good maternal nutrition the best start in life. World Health Organization (2016).

de Benua, B., Shvets, O.V. “Elimination of iodine deficiency is one of the key tasks of health care.” International Endocrinology Journal 6.38 (2011): 9–17.

Tatarchuk, T.F., Bulavenko, O.V., Kapshuk, I.M., Таrnopolska, V.O. “Vitaine D deficiency in the genesis of reproductive health disorders.” Ukr Med Journal 5.109 (IX/X) (2015): 56–61.

Tatarchuk, T.F., Dubossarska, Y.A., Mamenko, M.E. “Iodine deficiency: global challenge on which we can and must response.” Health of Ukraine 3.23 (2016): 12–3.

Primary prevention of EUROCAT. Available from: [http://www.eurocat-network.eu/default.aspx?tree=preventionandriskfactors %2fprimaryprevention], last accessed May 16, 2017.

Weisberg, I., Tran, P., Christensen, B., et al. “A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity.” Mol Genet Metab 64.3 (1998): 169–72.

Zaganjor, I., Sekkarie, A., Tsang, B.L., et al. “Describing the prevalence of neural tube defects worldwide: a systematic literature review.” PLoS One 11.4 (2016): e0151586.

Recommendations of Centers for Disease Control and Prevention. Available from: [https://www.cdc.gov/ncbddd/folicacid/recommendations.html], last accessed May 16, 2017.

Royal College of Obstetricians and Gynecologists. “Best practice in postpartum family planning.” Best Practice Paper 1 (2015).

Bocanegra, T., et al. “Interpregnancy intervals: impact of postpartum contraceptive effectiveness and coverage.” Am J Obstet Gynecol 210.4 (2014): 311.e1–8.

SOGC Clinical Practice Guideline. “Canadian Contraception Consensus (Part 3 of 4): Chapter 7 – Intrauterine Contraception.” Am J Obstet Gynecol 38.2 (2016): 182–222.

Rebecca, H., et al. “Contraception in women over 40 years of age.” CMAJ 185.7 (2013): 565–73.

Jensen, J.T. “Evaluation of a new estradiol oral contraceptive: estradiol valerate and dienogest.” Expert Opin Pharmacother 11 (2010): 1147–57.

Junge, W., Mellinger, U., Parke, S., Serrani, M. Metabolic and haemostatic effects of estradiol valerate/dienogest. А novel oral contraceptive: a randomized, open-labeL single centre study.” Clin Drug lnvestig 31 (2011): 573–84.

Palacios, S., et al. “Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiolvalerate/ dienogest): a Phase III trial.” Eur J Obstet Gynecol Reprod Biol 149.1 (2010): 57–62.

Burlaka, O. “The therapeutic possibilities of continuous mode of oral contraceptives for Ukrainian military women in ATO zone.” Goirnale Italiano di Ostetricia e Ginecologia XXXVIII.1 (2016): 58–9.

Trego, L.L. “Military women’s menstrual experiences and interest in menstrual suppression during deployment.” J Obstet Gynecol Neonatal Nurs 36.4 (2007): 342–7.

Powell-Dunford, N.C., et al. “Menstrual suppression for combat operations: advantages of oral contraceptive pills.” Womens Health Issues 21.1 (2011): 86–91.

Minkin, M.J. “The Importance of IUD Contraception in Military Mothers.” Federal practitioner supplement 30.6 (2013): 1–6.

Dougherty, P.L. “Menstrual suppression benefits and risks of continuous combined oral contraceptives.” Nursing for Women’s Health 12.3 (2008): 243–8.

National Consensus regarding management of patients in climacteric period. Reproductive endocrinology 1.27 (2016): 8–25.

McGraw, K. “Gender differences among military combatants. Doessocial support, ostracism, and pain perception influence psychological health?” Military Medicine 181.1 (2016): 80–5.

World Health Organization. Medical eligibility criteria for contraceptive use, 5-th ed (2015). Available from [http://apps.who. int/iris/bitstream/10665/181468/1/9789241549158_ eng.pdf?ua=1], last accessed Mar 22, 2017.

Abnormal uterine bleedings. Unified clinical protocol of primary, secondary (specialized) and tertiary (highly specialized) medical care, approved by the Order of the MOH of Ukraine No. 353 from 13.04.2016.

Soini, T., et al. “Impact of levonorgestrel-releasing intrauterine system use on the cancer risk of the ovary and fallopian tube.” ActaOncol 55.11 (2016): 1281–4.

Sheng, J., et al. “The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis.” Contraception 79 (2009): 189–93.

Piepoli, M.F., et al. “European Guidelines on cardiovascular disease prevention in clinical practice.” Eur Heart J 37.29 (2016): 2315–81.

Homocysteine Studies Collaboration. “Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis.” JAMA 288.16 (2002): 2015–22.

Centers for disease control and prevention. “Providing quality family planning services. Recommendations of CDC and the U.S. office of population affairs.” MMWR 63.4 (2014).

World Health Organization. Health-2020. An European policy framework supporting action across government and society for health and well-being (2013).

Canadian Consensus on Female Nutrition. “Adolescence, Reproduction, Menopause, and Beyond.” J Obstet Gynaecol Can 38.6 (2016): 508–54.

Mahvash Shere, et al. “The effectiveness of folate-fortified oral contraceptives in maintaining optimal folate levels to protect against neural tube defects: a systematic review.” Obstet Gynaecol Can 37.6 (2015): 527–33.

Homocysteine Lowering Trialists’ Collaboration. “Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials.” Am J Clin Nutr 82.4 (2005): 806–12.

Cancer in Ukraine, 2014–2015. Ed. by O.O. Kolesnyk. Fact sheet of National cancer register of Ukraine #17. Kyiv (2016).

World Health Organization. Global strategy for women’s, children’s and adolescents’ health, 2016–2030. Available from: [http://www.who.int/life-course/publications/global-strategy-2016-2030/en/], last accessed May 16, 2017.

Atef Darwish. Contemporary Gynecologic Practice (2015). Available from: [http://www.intechopen.com/ books/contemporary-gynecologic-practice/endometrial-cancer-prevention-with-levonorgestrelreleasing- intrauterine-system], last accessed May 16, 2017.

World Health Organization. Daily iron supplementation in adult women and adolescent girls. Guideline. Geneva (2016): 34 р.

Contraception methods according to life periods. Learning guide. Kyiv (2013).

Order of the MOH of Ukraine No.59 from 21.01.2014. Unified clinical protocols of primary, secondary (specialized), tertiary (highly specialized) medical care “Family Planning”.


GOST Style Citations


1. Евсина, О.В. Качество жизни в медицине – важный показатель состояния здоровья пациента / О.В. Евсина // Электронный научный журнал «Личность в меняющемся мире: здоровье, адаптация, развитие». – 2013. №1. – С. 119–133.

2. Наказ МОЗ та Національної академії медичних наук України № 1030/102 від 29.11.2013 р. «Про вдосконалення системи планування сім’ї та охорони репродуктивного здоров’я в Україні».

3. Здоровое питание матери: лучшее начало жизни. Всемирная организация здравоохранения, 2016.

4. де Бенуа, Б. Устранение дефицита йода – одна из ключевых задач здравоохранения / Б. де Бенуа, О.В. Швец // Международный эндокринологический журнал. – 2011. – №6 (38). – С. 9–17.

5. Татарчук, Т.Ф. Недостатність вітаміну D в генезі порушень репродуктивного здоров’я / Т.Ф. Татарчук, О.В. Булавенко, І.М. Капшук, В.О. Тарнопольська // Укр. мед. часопис. – 2015. – № 5 (109) – IX/X. – С. 56–61.

6. Татарчук, Т.Ф. Йододефицит: глобальный вызов, на который мы можем и должны ответить / Т.Ф. Татарчук, Ю.А. Дубоссарская, М.Е Маменко // Здоров’я України. – 2016. – №3 (23). – С. 12–13.

7. Primary prevention of EUROCAT. Available from: [http://www.eurocat-network.eu/default.aspx?tree=preventionandriskfactors %2fprimaryprevention], last accessed May 16, 2017.

8. Weisberg, I., Tran, P., Christensen, B., et al. “A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity.” Mol Genet Metab 64.3 (1998): 169–72.

9. Zaganjor, I., Sekkarie, A., Tsang, B.L., et al. “Describing the prevalence of neural tube defects worldwide: a systematic literature review.” PLoS One 11.4 (2016): e0151586.

10. Recommendations of Centers for Disease Control and Prevention. Available from: [https://www.cdc.gov/ncbddd/folicacid/recommendations.html], last accessed May 16, 2017.

11. Royal College of Obstetricians and Gynecologists. “Best practice in postpartum family planning.” Best Practice Paper 1 (2015).

12. Bocanegra, T., et al. “Interpregnancy intervals: impact of postpartum contraceptive effectiveness and coverage.” Am J Obstet Gynecol 210.4 (2014): 311.e1–8.

13. SOGC Clinical Practice Guideline. “Canadian Contraception Consensus (Part 3 of 4): Chapter 7 – Intrauterine Contraception.” Am J Obstet Gynecol 38.2 (2016): 182–222.

14. Rebecca, H., et al. “Contraception in women over 40 years of age.” CMAJ 185.7 (2013): 565–73.

15. Jensen, J.T. “Evaluation of a new estradiol oral contraceptive: estradiol valerate and dienogest.” Expert Opin Pharmacother 11 (2010): 1147–57.

16. Junge, W., Mellinger, U., Parke, S., Serrani, M. Metabolic and haemostatic effects of estradiol valerate/dienogest. А novel oral contraceptive: a randomized, open-labeL single centre study.” Clin Drug lnvestig 31 (2011): 573–84.

17. Palacios, S., et al. “Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiolvalerate/ dienogest): a Phase III trial.” Eur J Obstet Gynecol Reprod Biol 149.1 (2010): 57–62.

18. Burlaka, O. “The therapeutic possibilities of continuous mode of oral contraceptives for Ukrainian military women in ATO zone.” Goirnale Italiano di Ostetricia e Ginecologia XXXVIII.1 (2016): 58–9.

19. Trego, L.L. “Military women’s menstrual experiences and interest in menstrual suppression during deployment.” J Obstet Gynecol Neonatal Nurs 36.4 (2007): 342–7.

20. Powell-Dunford, N.C., et al. “Menstrual suppression for combat operations: advantages of oral contraceptive pills.” Womens Health Issues 21.1 (2011): 86–91.

21. Minkin, M.J. “The Importance of IUD Contraception in Military Mothers.” Federal practitioner supplement 30.6 (2013): 1–6.

22. Dougherty, P.L. “Menstrual suppression benefits and risks of continuous combined oral contraceptives.” Nursing for Women’s Health 12.3 (2008): 243–8.

23. Національний консенсус щодо ведення пацієнток у клімактерії. Репродуктивна ендокринологія. –2016. – №1 (27). – C. 8–25.

24. McGraw, K. “Gender differences among military combatants. Doessocial support, ostracism, and pain perception influence psychological health?” Military Medicine 181.1 (2016): 80–5.

25. World Health Organization. Medical eligibility criteria for contraceptive use, 5-th ed (2015). Available from [http://apps.who. int/iris/bitstream/10665/181468/1/9789241549158_ eng.pdf?ua=1], last accessed Mar 22, 2017.

26. Аномальні маткові кровотечі. Уніфікований клінічний протокол первинної, вторинної (спеціалізованої) та третинної (високоспеціалізованої) медичної допомоги, затверджений наказом МОЗ України від 13.04.2016 р. № 353.

27. Soini, T., et al. “Impact of levonorgestrel-releasing intrauterine system use on the cancer risk of the ovary and fallopian tube.” ActaOncol 55.11 (2016): 1281–4.

28. Sheng, J., et al. “The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis.” Contraception 79 (2009): 189–93.

29. Piepoli, M.F., et al. “European Guidelines on cardiovascular disease prevention in clinical practice.” Eur Heart J 37.29 (2016): 2315–81.

30. Homocysteine Studies Collaboration. “Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis.” JAMA 288.16 (2002): 2015–22.

31. Centers for disease control and prevention. “Providing quality family planning services. Recommendations of CDC and the U.S. office of population affairs.” MMWR 63.4 (2014).

32. Всемирная организация здравоохранения. Здоровье-2020: основы европейской политики в поддержку действий всего государства и общества в интересах здоровья и благополучия. 2013 г.

33. Canadian Consensus on Female Nutrition. “Adolescence, Reproduction, Menopause, and Beyond.” J Obstet Gynaecol Can 38.6 (2016): 508–54.

34. Mahvash Shere, et al. “The effectiveness of folate-fortified oral contraceptives in maintaining optimal folate levels to protect against neural tube defects: a systematic review.” Obstet Gynaecol Can 37.6 (2015): 527–33.

35. Homocysteine Lowering Trialists’ Collaboration. “Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials.” Am J Clin Nutr 82.4 (2005): 806–12.

36. Рак в Україні, 2014–2015 рр. Під редакцією O.O. Колесник. – Бюлетень національного канцер-реєстру України №17. – Київ, 2016.

37. World Health Organization. Global strategy for women’s, children’s and adolescents’ health, 2016–2030. Available from: [http://www.who.int/life-course/publications/global-strategy-2016-2030/en/], last accessed May 16, 2017.

38. Atef Darwish. Contemporary Gynecologic Practice (2015). Available from: [http://www.intechopen.com/ books/contemporary-gynecologic-practice/endometrial-cancer-prevention-with-levonorgestrelreleasing- intrauterine-system], last accessed May 16, 2017.

39. World Health Organization. Daily iron supplementation in adult women and adolescent girls. Guideline. Geneva (2016): 34 р.

40. Методи контрацепції відповідно до періодів життя. Навчальний посібник. Київ, 2013.

41. Наказ МОЗ України від 21.01.2014 р. № 59. Уніфікований клінічний протокол первинної, вторинної (спеціалізованої), третинної (високоспеціалізованої) медичної допомоги «Планування сім’ї».





DOI: https://doi.org/10.18370/2309-4117.2017.35.7-16

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

ISSN 2411-1295 (Online), ISSN 2309-4117 (Print)